Body weight
downin humans3
HRS-7535 decreases body weight in humans (−2.4% versus −0.7% with placebo).
“Body weight loss was -2.4% in the HRS-7535 60 mg group vs -0.7% in the placebo group.”
Human trialType 2 diabetes treated with background metformin and SGLT2 inhibitorsoral tablets60 mg once daily16 weeks
HRS-7535 improved blood-sugar control in type 2 diabetes
Diabetologia14 Oct 2026
HRS-7535 decreases body weight in humans (-2.63% vs. -1.30% for PBO).
“At wk 16, the LS mean percentage change in BW reached -2.63% for the 90 mg group vs. -1.30% for PBO.”
Human trialin T2DM participants inadequately controlled on metformin90 mg16 weeks
ADA Scientific Sessions 2025 abstract13 Jun 2025
HRS-7535 decreases body weight in humans (-4.67% to -6.87% PBO-adjusted LS mean change at wk 26).
“In obese adults without diabetes, HRS-7535 at doses of 60, 120, or 180 mg QD resulted in clinically meaningful and statistically significant reductions in BW at wk 26 compared with PBO.”
Human trialobese adults without diabetes60, 120, or 180 mg QD26 wks
Efficacy and Safety of a Novel Oral Small Molecule GLP-1RA in Chinese Obese Adults without Diabetes
ADA Scientific Sessions 2025 abstract13 Jun 2025
HbA1c
downin humans2
HRS-7535 decreases HbA1c in humans (Change from baseline: −16 mmol/mol (95% CI −19, −14) at 30 mg; −20 mmol/mol (95% CI −22, −17) at 60 mg; −4 mmol/mol (95% CI −7, −2) with placebo).
“Treatment with HRS-7535 resulted in significant improvements in glycaemic management in participants with type 2 diabetes”
Human trialChinese participants with type 2 diabetes inadequately controlled by metformin and SGLT2 inhibitorsoral tablets30 mg or 60 mg once daily16 weeksn = 155
HRS-7535 improved blood-sugar control in type 2 diabetes
Diabetologia14 Oct 2026
HRS-7535 decreases HbA1c in humans (-0.94% to -1.57% (P<0.001 vs PBO)).
“At wk 16, the PBO-adjusted least-squares (LS) mean changes in HbA1c for HRS-7535 doses of 15, 30, 60, and 90 mg were -0.94%, -1.34%, -1.57%, and -1.39%, respectively”
Human trialin T2DM participants inadequately controlled on metformin16 weeks
ADA Scientific Sessions 2025 abstract13 Jun 2025
Achievement of HbA1c <53 mmol/mol
upin humans1
HRS-7535 increases achievement of HbA1c <53 mmol/mol in humans (51.0% at 30 mg and 66.0% at 60 mg versus 9.8% with placebo).
“were 51.0% in the HRS‐7535 30 mg group, 66.0% in the HRS‐7535 60 mg group, and 9.8% in the placebo group”
Human trialType 2 diabetes treated with background metformin and SGLT2 inhibitorsoral tablets30 mg or 60 mg once daily16 weeksn = 155
HRS-7535 improved blood-sugar control in type 2 diabetes
Diabetologia14 Oct 2026
Fasting plasma glucose
downin humans1
HRS-7535 decreases fasting plasma glucose in humans.
“At wk 16, HRS-7535 showed dose-related reductions in FPG, 2h-PG, and waist circumference.”
Human trialin T2DM participants inadequately controlled on metformin16 weeks
ADA Scientific Sessions 2025 abstract13 Jun 2025
A blood-sugar measure fell 16 and 20 mmol/mol with 30 mg and 60 mg daily, versus 4 mmol/mol with placebo over 16 weeks.A blood-sugar measure fell 16 and 20 mmol/mol with 30 mg and 60 mg daily, versus 4 mmol/mol with placebo over 16 weeks.